Oral composition, and method for suppressing bitterness from ergothioneine or salt thereof and odor from chondroitin sulfate or salt thereof

Abstract

The present invention addresses the problem of providing an oral composition in which bitterness derived from ergothioneine or a salt thereof and odor derived from chondroitin sulfate or a salt thereof are suppressed despite containing ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof. The present invention pertains to an oral composition characterized by containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, the weight ratio of component (B) (in terms of chondroitin sulfate) to component (A) (in terms of ergothioneine), i.e., (B) / (A), being 2-60.

Description

Technical Field

[0001] The present invention relates to an oral composition containing ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof. In addition, the present invention relates to a method for suppressing the bitter taste derived from ergothioneine and the odor derived from chondroitin sulfate or a salt thereof. Background Art

[0002] Ergothioneine is one of the hydrophilic sulfur-containing amino acids, and is known to have various physiological activities including antioxidant activity. Regarding the physiological activities of ergothioneine, for example, Patent Document 1 reports an effect of promoting the production of immune response-activating cytokines. Since ergothioneine has various physiological activities, it has attracted much attention as a food, cosmetic or pharmaceutical product in recent years.

[0003] Chondroitin sulfate is a type of acidic mucopolysaccharide. In animals, it exists in the form of a proteoglycan covalently bonded to a core protein, which is generally called a core protein. Chondroitin sulfate is present in various tissues of animals, such as cartilage, connective tissue such as skin, and brain tissue. It is particularly present in the extracellular matrix of cartilage and can be used in health foods to improve symptoms such as osteoarthritis.

[0004] Patent Literature Patent Document 1: Japanese Patent Application Publication No. 2017-218431 Summary of the invention

[0005] As mentioned above, because thioneine possesses useful physiological activity, the food such as the supplement containing thioneine or its salt is useful for maintaining or promoting health. However, thioneine or its salt has unique fragrance, especially has bitter taste (bitter feeling) like pricking tongue, and still has room for improvement in making oral compositions. Furthermore, chondroitin sulfate has a fishy smell, which may sometimes be a problem when it is formulated into an oral composition.

[0006] The object of the present invention is to provide a kind of oral composition, although it contains thioneine or its salt and chondroitin sulfate or its salt, the bitter taste from thioneine or its salt and the stench from chondroitin sulfate or its salt are suppressed. In addition, the object of the present invention is to provide a method for suppressing the bitter taste from thioneine or its salt and the stench from chondroitin sulfate or its salt.

[0007] The present inventors have conducted intensive studies to solve the above problems and have found that the bitter taste derived from ergothioneine or its salt and the odor derived from chondroitin sulfate or its salt can be suppressed by combining ergothioneine or its salt and chondroitin sulfate or its salt at a specific ratio.

[0008] The present invention includes the following compositions and the like. [1] An oral composition comprising the following ingredients (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, The weight ratio of the component (B) (calculated as chondroitin sulfate) to the component (A) (calculated as ergothioneine), that is, (B) / (A) is 2 to 60. [2] The composition according to [1] above, which is a food or beverage. [3] A method for suppressing the bitter taste derived from ergothioneine or its salt and the odor derived from chondroitin sulfate or its salt, characterized in that, in an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, The weight ratio of the component (B) (calculated as chondroitin sulfate) to the component (A) (calculated as ergothioneine), that is, (B) / (A) is adjusted to 2 to 60.

[0009] According to the present invention, a kind of oral composition can be provided, although it contains thioneine or its salt and chondroitin sulfate or its salt, the bitter taste from thioneine or its salt and the stink from chondroitin sulfate or its salt are suppressed. In addition, according to the present invention, a method for suppressing the bitter taste from thioneine or its salt and the stink from chondroitin sulfate or its salt can be provided. DETAILED DESCRIPTION

[0010] The oral composition of the present invention contains (A) ergothioneine or a salt thereof and (B) chondroitin sulfate or a salt thereof, wherein the weight ratio ((B) / (A)) of the component (B) (in terms of chondroitin sulfate) to the component (A) (in terms of ergothioneine) is 2 to 60.

[0011] Ergothioneine is a kind of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. As the salt of ergothioneine, as long as it is a pharmacologically acceptable salt or a salt allowed in a diet, there is no particular limitation, and it may be any of an acidic salt and an alkaline salt. As an acidic salt, for example, inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate can be listed; organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate can be listed. As an alkaline salt, for example, alkali metal salts such as sodium salt and potassium salt can be listed; alkaline earth metal salts such as calcium salt and magnesium salt can be listed.

[0012] Ergothioneine or its salt is not subject to any restrictions such as its form or manufacturing method. Ergothioneine or its salt can be a chemically synthesized product, or it can be a substance extracted or purified from a natural product. L-ergothioneine is contained in a large amount in the golden top pleurotus (Golden / Yellow Oyster Mushroom) (scientific name: Pleurotuscornucopiae var.citrinopileatus) of the mushroom belonging to the genus Pleurotus of the family Pleurotus. L-ergothioneine is also contained in mushrooms such as Agaricus bisporus (scientific name: Agaricus bisporus), Grey Oyster Mushroom (scientific name: Pleurotus ostreatus), Lentinula edodes (scientific name: Lentinula edodes), Grifola frondosa (scientific name: Grifola frondosa), Ganoderma lucidum (scientific name: Ganoderma lucidum), Hericium erinaceus (scientific name: Hericiumerinaceus), Agrocybe aegerita (scientific name: Agrocybe aegerita), Chanterelles (scientific name: Cantharelus cibarius), Boletus (scientific name: Boletus edulis), Morchella esculenta (scientific name: Morchella esculenta), etc. When L-ergothioneine is obtained from natural products, it is preferably extracted from Pleurotus eryngii. Ergothioneine or its salt can also be produced by microbial fermentation. Ergothioneine or its salt may be an isolated substance.

[0013] Chondroitin sulfate has a repeating disaccharide structure in which D-glucuronic acid or its diastereomer is bonded to N-acetyl-D-galactosamine, and is an acidic mucopolysaccharide in which at least a part of the hydroxyl groups of D-glucuronic acid or its diastereomer and N-acetyl-D-galactosamine are sulfated. Examples of the epimer of D-glucuronic acid include iduronic acid, which is a C5 epimer. There is no particular limitation on the chondroitin sulfate, and examples thereof include: chondroitin sulfate A having a structural unit derived from glucuronic acid and a structural unit derived from N-acetylgalactosamine tetrasulfate; chondroitin sulfate B having a structural unit derived from iduronic acid disulfate and a structural unit derived from N-acetylgalactosamine tetrasulfate; chondroitin sulfate C having a structural unit derived from glucuronic acid and a structural unit derived from N-acetylgalactosamine hexasulfate; chondroitin sulfate D having a structural unit derived from glucuronic acid disulfate and a structural unit derived from N-acetylgalactosamine hexasulfate; chondroitin sulfate E having a structural unit derived from glucuronic acid and a structural unit derived from N-acetylgalactosamine 4,6-disulfate; chondroitin sulfate H having a structural unit derived from iduronic acid trisulfate and a structural unit derived from N-acetylgalactosamine tetrasulfate; chondroitin sulfate K having a structural unit derived from glucuronic acid disulfate and a structural unit derived from N-acetylgalactosamine 4,6-disulfate, and the like. Chondroitin sulfate is in the form of at least one selected from the group consisting of chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, chondroitin sulfate D, chondroitin sulfate E, chondroitin sulfate H, and chondroitin sulfate K, which is one of the preferred embodiments of the present invention.

[0014] Chondroitin sulfate has a fishy odor. The composition of the present invention can reduce the bitter taste derived from ergothioneine or its salt by containing chondroitin sulfate or its salt. By combining chondroitin sulfate or a salt thereof with ergothioneine or a salt thereof, it is also possible to suppress the odor derived from chondroitin sulfate or a salt thereof. Therefore, continuous ingestion of ergothioneine or a salt thereof and chondroitin sulfate or a salt thereof can be facilitated.

[0015] The salt of chondroitin sulfate is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable in food and beverages, and examples thereof include alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as calcium and magnesium. Alkali metal salts are preferred, and sodium salts are more preferred.

[0016] The chondroitin sulfate and its salt used in the present invention are not limited by their form or production method, and commercial products can be used, and substances extracted and purified from natural products can also be used. For example, in the case of chondroitin sulfate, it can be obtained by extracting chondroitin sulfate from cartilaginous fish such as sharks, bony fish such as salmon and trout, mollusks such as squid, and cartilage of animals such as cattle, pigs, and chickens.

[0017] In the composition of the present invention, the weight ratio of component (B) (calculated as chondroitin sulfate) to component (A) (calculated as ergothioneine) ((B) calculated as chondroitin sulfate / (A) calculated as ergothioneine) is 2 to 60. Ergothioneine or its salt has bitter taste like pricking the tongue. In addition, chondroitin sulfate or its salt also has bad smell. In the composition containing components (A) and (B), when the weight ratio ((B) / (A)) of component (B) (chondroitin sulfate conversion) relative to component (A) (ergothioneine conversion) is above range, the bitter taste from component (A) can be suppressed, and the bad smell from component (B) can also be suppressed simultaneously. Therefore, the continuous intake of ergothioneine or its salt and chondroitin sulfate or its salt can be made easy. The weight ratio ((B) / (A)) is preferably 3-55, more preferably 4-50, further preferably 5-45, particularly preferably 6-40, and most preferably 7-35.

[0018] The content of ergothioneine or a salt thereof contained in the composition of the present invention is not particularly limited and can be set according to its form and the like. The content of thioneine or its salt in the composition of the present invention, calculated with thioneine, for example, preferably 0.05% by weight or more in the composition, more preferably 0.1% by weight or more, further preferably 0.5% by weight or more, further preferably 0.6% by weight or more, further preferably 0.8% by weight or more, particularly preferably 1% by weight or more, in addition, preferably 30% by weight or less, more preferably 20% by weight or less, further preferably 10% by weight or less. In one embodiment, the content of thioneine or its salt is calculated with thioneine, preferably 0.05-30% by weight in the composition of the present invention, more preferably 0.1-30% by weight, further preferably 0.5-30% by weight, further preferably 0.6-20% by weight, further preferably 0.8-20% by weight, particularly preferably 1-10% by weight. When the composition of the present invention contains two or more compounds as thioneine or its salt, the content of thioneine or its salt refers to their total content. The content of thioneine can be measured by high performance liquid chromatography (HPLC). The amount of ergothioneine or its salt converted to ergothioneine or an expression similar thereto, in the case of ergothioneine, refers to the amount thereof. In the case of a salt of ergothioneine, it refers to the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.

[0019] The content of chondroitin sulfate or a salt thereof contained in the composition of the present invention is not particularly limited and can be set according to its form and the like. The content of chondroitin sulfate or its salt in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.2% by weight or more, and further preferably 1% by weight or more in the composition, calculated as chondroitin sulfate, and is preferably 99% by weight or less, more preferably 98% by weight or less, further preferably 95% by weight or less, further preferably 90% by weight or less, and particularly preferably 85% by weight or less. In one embodiment, the content of chondroitin sulfate or its salt is preferably 0.1 to 99% by weight, more preferably 0.2 to 98% by weight, further preferably 0.2 to 95% by weight, further preferably 1 to 90% by weight, and particularly preferably 1 to 85% by weight in the composition of the present invention, calculated as chondroitin sulfate. In one embodiment, the content of chondroitin sulfate or its salt may be 0.2 to 50% by weight, 0.4 to 40% by weight, 0.5 to 30% by weight, 0.8 to 20% by weight, or 1 to 10% by weight in terms of chondroitin sulfate. When the composition of the present invention contains two or more compounds as chondroitin sulfate or its salt, the content of chondroitin sulfate or its salt means the total content of these compounds. The content of chondroitin sulfate or a salt thereof can be measured by HPLC. The amount of chondroitin sulfate or its salt converted to chondroitin sulfate or similar expressions means the amount in the case of chondroitin sulfate, and means the value obtained by multiplying the number of moles of the salt by the molecular weight of chondroitin sulfate in the case of a salt of chondroitin sulfate.

[0020] The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 1 to 100 mg, more preferably 2 to 50 mg, further preferably 5 to 25 mg, particularly preferably 5 to 20 mg, in terms of ergothioneine per daily intake for adults. The content of chondroitin sulfate or a salt thereof in the composition of the present invention is preferably 2 to 200 mg, more preferably 4 to 150 mg, and even more preferably 5 to 100 mg in terms of chondroitin sulfate per daily intake for adults.

[0021] Ergothioneine or its salt and chondroitin sulfate or its salt are contained in natural products or food and drink, and are compounds with edible experience.Therefore from the perspective of safety, it is generally believed that ergothioneine or its salt and chondroitin sulfate or its salt, for example, have fewer problems in daily intake.According to the present invention, a kind of high safety can be provided, and the bitter taste from ergothioneine or its salt and the stink from chondroitin sulfate or its salt are alleviated and the composition easily taken in.

[0022] As described above, ergothioneine or its salt is known to exert a variety of physiological activities or health functions, for example, it is known to have an antioxidant effect, a brain function improvement effect, an anti-aging effect, an eye disease improvement effect, a whitening effect, an ultraviolet absorption effect, a melanin production inhibitory effect, an active oxygen elimination effect, an elastase activity inhibitory effect, a wrinkle formation inhibitory effect, a skin relaxation inhibitory effect, an autophagy promoting effect, etc. Therefore, the composition of the present invention can be suitably used for anti-oxidation, brain function improvement, anti-aging, eye disease, whitening, ultraviolet absorption, melanin production inhibition, active oxygen elimination, elastase activity inhibition, wrinkle formation inhibition, skin sagging inhibition, autophagy promotion, etc.

[0023] Chondroitin sulfate or its salt is known to exert health functions such as improving pain in osteoarthritis of the knee or hip, etc. Since the composition of the present invention contains chondroitin sulfate or its salt, it can also be used to obtain the above-mentioned effects exerted by these substances.

[0024] The composition of the present invention can be used for either therapeutic use (medical use) or non-therapeutic use (non-medical use). The term "non-therapeutic" refers to a concept that does not include medical behavior, that is, human surgery, treatment or diagnosis. The composition of the present invention can be in the form of food and beverage, medicine, quasi-drug, feed, etc. The composition of the present invention can also be a raw material or preparation used by being formulated into food and beverage, medicine, quasi-drug, feed, etc.

[0025] The composition of the present invention is an oral composition. Specific examples of the oral composition include foods and drinks, oral pharmaceuticals, quasi-drugs, and feeds. Foods and drinks or oral pharmaceuticals are preferred, and foods and drinks are more preferred.

[0026] As long as the effect of the present invention is not damaged, the composition of the present invention can also contain any additive, any composition on the basis of thioneine or its salt and chondroitin sulfate or its salt.These additives and composition can be selected according to the form of the composition, and can use the material that can be generally used for oral compositions such as food and drink, pharmaceuticals, quasi-drugs, feeds, etc. When the composition of the present invention is made into food and drink, pharmaceuticals, quasi-drugs, feeds, etc., its manufacture method is not particularly limited, and can be manufactured by a general method.In a way, the composition of the present invention can be a material consisting of thioneine or its salt and chondroitin sulfate or its salt. The form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.

[0027] For example, when the composition of the present invention is made into food and drink, it is possible to prepare the composition (for example, food raw material, food additive used as required, etc.) that can be used for food and drink in ergothioneine or its salt and chondroitin sulfate or its salt, and make various food and drink. Food and drink are not particularly limited, and for example, can be enumerated: general food and drink, health food, health supplement food, health drink, functional label food, specific health food, patient food and drink, etc. Above-mentioned health food, health supplement food, functional label food, specific health food, etc., for example, can be used in the various preparation forms of granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, drinks, liquid food, etc.

[0028] When the composition of the present invention is made into pharmaceuticals or quasi-medical products, for example, in ergothioneine or its salt and chondroitin sulfate or its salt, the carrier allowed in pharmacology, the additive added as required, etc., are prepared, and the pharmaceuticals or quasi-medical products of various dosage forms are made. Such carriers, additives, etc., as long as they are materials allowed in pharmacology that can be used for pharmaceuticals or quasi-medical products, for example, can be enumerated: one or more than two of excipients, binding agents, disintegrants, lubricants, antioxidants, coloring agents, etc. As the dosage form for oral administration of pharmaceuticals or quasi-medical products, can be enumerated: liquid, tablet, powder, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewing agents, etc.

[0029] When the composition of the present invention is made into feed, ergothioneine or its salt and chondroitin sulfate or its salt are simply blended into the feed. Feed additives are also included in the feed. As feed, for example, feed for livestock such as cattle, pigs, chickens, sheep, horses, etc.; feed for small animals such as rabbits, rats, mice, etc.; pet food for dogs, cats, small birds, etc., etc.

[0030] The subject to which the composition of the present invention is ingested or administered (may also be referred to as the subject to be administered) is not particularly limited, but is preferably a human or a non-human mammal, and more preferably a human.

[0031] The present invention also includes the following methods. A method for suppressing bitterness from ergothioneine or its salt and odor from chondroitin sulfate or its salt, characterized in that, in an oral composition containing (A) ergothioneine or its salt and (B) chondroitin sulfate or its salt, the weight ratio ((B) / (A)) of component (B) (chondroitin sulfate conversion) relative to component (A) (ergothioneine conversion) is adjusted to 2 to 60. In the preparation of the oral composition, by adjusting the weight ratio ((B) / (A)) of component (B) (chondroitin sulfate conversion) to component (A) (ergothioneine conversion) to the above range, an oral composition in which the bitter taste from ergothioneine or its salt and the odor from chondroitin sulfate or its salt are suppressed can be obtained.

[0032] By the above method, the bitter taste from ergothioneine or its salt and the odor from chondroitin sulfate or its salt can be effectively suppressed. By suppressing the bitter taste from ergothioneine or its salt and the odor from chondroitin sulfate or its salt, the taste of the oral composition can be improved. In the above method, thioneine or its salt and chondroitin sulfate or its salt and their preferred embodiment are the same as the oral composition of the present invention described above. The preferred range of the weight ratio ((B) / (A)) of component (B) (chondroitin sulfate conversion) relative to component (A) (thioneine conversion) is also the same as the oral composition of the present invention.

[0033] According to the above method, bitterness derived from ergothioneine or its salt and odor derived from chondroitin sulfate or its salt can be suppressed, and other methods can be combined as a method for suppressing these unpleasant flavors. Other methods of suppressing the unpleasant flavor include, for example, a method of adding a sweetener or a flavoring agent to the component having the unpleasant flavor to prepare a formulation; a method of coating the component with a sugar coating to prepare a formulation; or a method of sealing the component in a capsule to prepare a formulation.

[0034] Chondroitin sulfate or its salt is useful for suppressing the bitterness of thioneine or its salt. The present invention also includes a kind of application of (B) chondroitin sulfate or its salt, which is used to suppress the bitterness from (A) thioneine or its salt. With regard to the usage amount of chondroitin sulfate or its salt, it is preferred that the weight ratio ((B) / (A)) of (B) chondroitin sulfate or its salt (chondroitin sulfate conversion) relative to (A) thioneine or its salt (thioneine conversion) reaches 2 or more, and more preferably the above-mentioned weight ratio reaches 2 to 60.

[0035] Ergothioneine or its salt is useful for suppressing the odor of chondroitin sulfate or its salt. The present invention also includes a use of (A) ergothioneine or its salt for suppressing the odor from (B) chondroitin sulfate or its salt. With regard to the usage amount of ergothioneine or its salt, it is preferred that the weight ratio ((B) / (A)) of (B) chondroitin sulfate or its salt (chondroitin sulfate conversion) relative to (A) ergothioneine or its salt (ergothioneine conversion) reaches an amount of 2 or more, and more preferably the above-mentioned weight ratio reaches an amount of 2 to 60.

[0036] In this specification, the numerical range represented by the lower limit and the upper limit, i.e., "lower limit - upper limit", includes the lower limit and the upper limit. For example, the range represented by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit can be set as a range of any combination. Example

[0037] The present invention will be described in more detail below based on examples. However, the present invention is not limited to these examples.

[0038] The materials used in the following evaluation tests are as follows. (A) Ergothioneine: Raw material containing 100% L-ergothioneine (B) Chondroitin sulfate: Contains 70% of chondroitin sulfate from sharks

[0039] <Example 1: Flavor evaluation test of a composition containing ergothioneine and chondroitin sulfate> Compositions containing ergothioneine and chondroitin sulfate were prepared and subjected to sensory evaluation by three panelists skilled in sensory evaluation. The above (A) and (B) were mixed in the amounts shown in Table 1 to prepare compositions of samples 1 to 6 (compositions containing ergothioneine and chondroitin sulfate). The weight ratios of (B) / (A) in the compositions of samples 1 to 6 ((B) / (A) converted to chondroitin sulfate) are shown in Table 1. Three panelists each placed the total amount of the prepared composition (for example, in sample 1, a total of 20 mg of (A) 10 mg and (B) 10 mg) directly on the tongue, and evaluated the bitterness intensity from ergothioneine and the odor intensity from chondroitin sulfate according to the following criteria.

[0040] Evaluation criteria for bitterness from (A) ergothioneine The bitterness intensity of only the above-mentioned (A) (10 mg) was set to 5 points (control group 1), and the case where no bitterness derived from ergothioneine was felt was set to 1 point, and the evaluation was performed from 1 to 5 points (5 levels). The evaluations of the three panelists were counted, and the average values ​​are shown in Table 1. 5 points: Strong bitterness from ergothioneine 4 points: Feel the bitter taste from ergothioneine 3 points: Slightly bitter taste from ergothioneine 2 points: The bitter taste from ergothioneine is not noticeable 1 point: No bitter taste from ergothioneine

[0041] (B) Evaluation criteria for odor from chondroitin sulfate Evaluation was performed on a scale of 1 to 5 points (5 levels), with the odor intensity of only the above-mentioned (B) (10 mg) being 5 points (control group 2) and the case where no odor derived from chondroitin sulfate was felt being 1 point. The evaluations of the three panelists were counted, and the average values ​​are shown in Table 1. 5 points: Strong odor from chondroitin sulfate 4 points: The odor from chondroitin sulfate is felt 3 points: Slightly detectable odor from chondroitin sulfate 2 points: The odor from chondroitin sulfate is not noticeable 1 point: No odor from chondroitin sulfate is detected

[0042] When the average values ​​of the evaluation of the bitter taste derived from ergothioneine and the evaluation of the odor derived from chondroitin sulfate are both less than 4.0 points, it is evaluated that the bitter taste derived from ergothioneine and the odor derived from chondroitin sulfate are suppressed.

[0043] [Table 1]

[0044] When chondroitin sulfate is not allocated, the bitter taste (control group 1) of the tongue-piercing from thioneine can be strongly felt. On the other hand, when only chondroitin sulfate is present, the stink (control group 2) from chondroitin sulfate can be strongly felt. (B) Chondroitin sulfate is in the sample 2-4 and sample 6 of 2-60 scopes with respect to the weight ratio ((B) / (A)) of (A) thioneine, and the bitter taste from thioneine and the stink from chondroitin sulfate are both effectively alleviated.

Claims

1. An oral composition, characterized in that Contains the following ingredients (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, The weight ratio of the component (B) (calculated as chondroitin sulfate) to the component (A) (calculated as ergothioneine), that is, (B) / (A) is 2 to 60.

2. The composition according to claim 1, characterized in that It is a food and drink.

3. A method for suppressing the bitter taste from ergothioneine or its salt and the odor from chondroitin sulfate or its salt, characterized in that, In an oral composition containing the following ingredients (A) and (B): (A) ergothioneine or a salt thereof, and (B) chondroitin sulfate or a salt thereof, The weight ratio of the component (B) (calculated as chondroitin sulfate) to the component (A) (calculated as ergothioneine), that is, (B) / (A), is adjusted to 2 to 60.

Images